Literature DB >> 16616471

Programming CD8+ T cells for effective immunotherapy.

Christian S Hinrichs1, Luca Gattinoni, Nicholas P Restifo.   

Abstract

The differentiation state of CD8+ T cells has emerged as a crucial determinant of their ability to respond to tumor and infection. Signals from T-cell receptors, co-stimulatory molecules and cytokine receptors direct the differentiation process. These signals 'program' sustained and heritable gene expression patterns that govern progressive differentiation and lineage commitment. The epigenetic mechanisms by which T cells are programmed are just beginning to be elucidated. Understanding the mechanisms that control CD8+ T-cell differentiation is important in the development of novel immunotherapy strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616471      PMCID: PMC1540013          DOI: 10.1016/j.coi.2006.03.009

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  71 in total

1.  Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin.

Authors:  Andrew M Intlekofer; Naofumi Takemoto; E John Wherry; Sarah A Longworth; John T Northrup; Vikram R Palanivel; Alan C Mullen; Christopher R Gasink; Susan M Kaech; Joseph D Miller; Laurent Gapin; Kenneth Ryan; Andreas P Russ; Tullia Lindsten; Jordan S Orange; Ananda W Goldrath; Rafi Ahmed; Steven L Reiner
Journal:  Nat Immunol       Date:  2005-11-06       Impact factor: 25.606

2.  Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

Authors:  Juhua Zhou; Xinglei Shen; Jianping Huang; Richard J Hodes; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

3.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

4.  IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response.

Authors:  Yongqing Li; Marie Bleakley; Cassian Yee
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

5.  Host-reactive CD8+ memory stem cells in graft-versus-host disease.

Authors:  Yi Zhang; Gerard Joe; Elizabeth Hexner; Jiang Zhu; Stephen G Emerson
Journal:  Nat Med       Date:  2005-11-20       Impact factor: 53.440

6.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

7.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Authors:  Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

8.  Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets.

Authors:  Tim Willinger; Tom Freeman; Hitoshi Hasegawa; Andrew J McMichael; Margaret F C Callan
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

9.  Human naive CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T cell factor-1) following antigen encounter in vitro and in vivo.

Authors:  Tim Willinger; Tom Freeman; Mark Herbert; Hitoshi Hasegawa; Andrew J McMichael; Margaret F C Callan
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

10.  Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes.

Authors:  Attilio Bondanza; Veronica Valtolina; Zulma Magnani; Maurilio Ponzoni; Katharina Fleischhauer; Mark Bonyhadi; Catia Traversari; Francesca Sanvito; Salvatore Toma; Marina Radrizzani; Simona La Seta-Catamancio; Fabio Ciceri; Claudio Bordignon; Chiara Bonini
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

View more
  33 in total

Review 1.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

2.  Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.

Authors:  Christian S Hinrichs; Zachary A Borman; Luca Gattinoni; Zhiya Yu; William R Burns; Jianping Huang; Christopher A Klebanoff; Laura A Johnson; Sid P Kerkar; Shicheng Yang; Pawel Muranski; Douglas C Palmer; Christopher D Scott; Richard A Morgan; Paul F Robbins; Steven A Rosenberg; Nicholas P Restifo
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

Review 3.  Toll-like receptors in tumor immunotherapy.

Authors:  Chrystal M Paulos; Andrew Kaiser; Claudia Wrzesinski; Christian S Hinrichs; Lydie Cassard; Andrea Boni; Pawel Muranski; Luis Sanchez-Perez; Douglas C Palmer; Zhiya Yu; Paul A Antony; Luca Gattinoni; Steven A Rosenberg; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

4.  Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

Authors:  Christian S Hinrichs; Zachary A Borman; Lydie Cassard; Luca Gattinoni; Rosanne Spolski; Zhiya Yu; Luis Sanchez-Perez; Pawel Muranski; Steven J Kern; Carol Logun; Douglas C Palmer; Yun Ji; Robert N Reger; Warren J Leonard; Robert L Danner; Steven A Rosenberg; Nicholas P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-24       Impact factor: 11.205

5.  Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children.

Authors:  M Hedman; M Faresjö; S Axelsson; J Ludvigsson; R Casas
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

6.  Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

Authors:  Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Douglas C Palmer; Luca Gattinoni; Nicholas P Restifo
Journal:  Blood       Date:  2009-06-26       Impact factor: 22.113

7.  T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.

Authors:  Navtej Kaur; Osama S Naga; Håkan Norell; Amir A Al-Khami; Matthew J Scheffel; Nitya G Chakraborty; Christina Voelkel-Johnson; Bijay Mukherji; Shikhar Mehrotra
Journal:  Cytokine       Date:  2011-05-23       Impact factor: 3.861

8.  Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.

Authors:  Yong Lu; Bangxing Hong; Haiyan Li; Yuhuan Zheng; Mingjun Zhang; Siqing Wang; Jianfei Qian; Qing Yi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

9.  Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase.

Authors:  Elmer B Santos; Raymond Yeh; James Lee; Yan Nikhamin; Blesida Punzalan; Blesserene Punzalan; Krista La Perle; Steven M Larson; Michel Sadelain; Renier J Brentjens
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

10.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors.

Authors:  François Ghiringhelli; Lionel Apetoh; Antoine Tesniere; Laetitia Aymeric; Yuting Ma; Carla Ortiz; Karim Vermaelen; Theocharis Panaretakis; Grégoire Mignot; Evelyn Ullrich; Jean-Luc Perfettini; Frédéric Schlemmer; Ezgi Tasdemir; Martin Uhl; Pierre Génin; Ahmet Civas; Bernhard Ryffel; Jean Kanellopoulos; Jürg Tschopp; Fabrice André; Rosette Lidereau; Nicole M McLaughlin; Nicole M Haynes; Mark J Smyth; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2009-09-20       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.